表紙
市場調査レポート

拡張型心筋症 : パイプライン分析

Dilated Cardiomyopathy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 246011
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
拡張型心筋症 : パイプライン分析 Dilated Cardiomyopathy - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 60 Pages
概要

拡張型心筋症(DCM)とは、左心室の拡張・衰弱により、心臓が血液を送り出す機能が低下する状態のことを指します。場合によっては、心臓を緩めて血液を十分に取り込むことが出来なくなります。時間が経つにつれ、心臓の他の心室にも影響が及んできます。

当レポートでは、世界各国での拡張型心筋症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

拡張型心筋症の概要

治療薬の開発

  • 拡張型心筋症向けパイプライン製品:概要
  • 拡張型心筋症向けパイプライン製品:比較分析

各企業で開発中の拡張型心筋症治療薬

大学/研究機関で研究中の拡張型心筋症治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

拡張型心筋症治療薬:開発中の製品の一覧(企業別)

拡張型心筋症治療薬:研究中の製品の一覧(大学/研究機関別)

拡張型心筋症治療薬の開発に従事している企業

  • Array BioPharma Inc.
  • Hemostemix Ltd
  • Kasiak Research Private Limited
  • Sanofi
  • Vericel Corporation

拡張型心筋症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ACP-01
  • ARRY-797
  • CAP-1002
  • 拡張型心筋症向け薬剤
  • ixmyelocel-T
  • Refacell-DCM
  • 拡張型心筋症向け小分子

拡張型心筋症治療薬:最新の薬剤プロファイル

拡張型心筋症治療薬:開発が休止状態の製品

拡張型心筋症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8247IDB

Summary

Global Markets Direct's, 'Dilated Cardiomyopathy - Pipeline Review, H2 2016', provides an overview of the Dilated Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
  • The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects
  • The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dilated Cardiomyopathy Overview
    • Therapeutics Development
  • Pipeline Products for Dilated Cardiomyopathy - Overview
  • Dilated Cardiomyopathy - Therapeutics under Development by Companies
  • Dilated Cardiomyopathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dilated Cardiomyopathy - Products under Development by Companies
  • Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
    • Array BioPharma Inc.
    • Capricor Therapeutics, Inc.
    • Hemostemix Ltd
    • Kasiak Research Private Limited
    • Sanofi
    • Vericel Corporation
  • Dilated Cardiomyopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARRY-797 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAP-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CIP-137401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Dilated Cardiomyopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixmyelocel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MYK-491 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Refacell-DCM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dilated Cardiomyopathy - Dormant Projects
  • Dilated Cardiomyopathy - Product Development Milestones
    • Featured News & Press Releases
      • Apr 04, 2016: Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet
      • Mar 29, 2016: Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions
      • Mar 28, 2016: Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
      • Mar 10, 2016: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy
      • Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
      • Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
      • Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
      • Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T
      • Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting
      • May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients
      • May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions
      • Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T
      • Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
      • Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
      • May 17, 2011: Aastrom To Present Results From Two Studies of Ixmyelocel-T At International Society For Cellular Therapy Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dilated Cardiomyopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2016
  • Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics, Inc., H2 2016
  • Dilated Cardiomyopathy - Pipeline by Hemostemix Ltd, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Sanofi, H2 2016
  • Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dilated Cardiomyopathy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Dilated Cardiomyopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top